Document is current
Any future updates will be listed below
-
Authors
Castelli, Sveva
Flaadt, Tim https://orcid.org/0000-0002-2729-9941
Schulze, Franziska
Thole-Kliesch, Theresa M.
Zirngibl, Felix https://orcid.org/0000-0003-1764-4841
Oevermann, Lena https://orcid.org/0000-0001-6828-1783
Künkele, Annette https://orcid.org/0000-0002-8406-5412
Astrahantseff, Kathy
Schulte, Stefanie
Duell, Louisa
Fuchs, Joerg
Simon, Thorsten https://orcid.org/0000-0002-3425-8451
Hero, Barbara https://orcid.org/0000-0003-4129-890X
Hundsdoerfer, Patrick
Rogasch, Julian M. M.
Lang, Peter https://orcid.org/0000-0001-7737-2142
Warmann, Steven
von Stackelberg, Arend
Schulte, Johannes H. https://orcid.org/0000-0003-0671-1201
Eggert, Angelika
Deubzer, Hedwig E. https://orcid.org/0000-0002-6115-4893
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113414)
Deutsche Krebshilfe (70113414)
Deutsche Krebshilfe (70113414)
Deutsche Kinderkrebsstiftung (2024.20)
Deutsche Forschungsgemeinschaft (493872418)
Deutsche Forschungsgemeinschaft (493872418)
Deutsche Forschungsgemeinschaft (493872418)
- License Information
-
More Information
Article History
Received: 18 January 2026
Revised: 11 April 2026
Accepted: 15 May 2026
First Online: 29 May 2026
Competing interests
: TS has received funding in the form of institutional payments from the German Childhood Cancer Foundation and consulting fees from Recordati Rare Diseases, Norgine Ltd., Amgen, and Merck KGaA. TF, PL, AE and HED have worked as consultants of Recordati Rare Diseases.
